StockData
QIAGEN N.V. logo

QIAGEN N.V. (QGEN) stock

QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026Score 10/30
$50.22−0.12 (-0.24%)

Close on Oct 30, 2026Market cap $10.89BP/E 25.9Yield 0.50%

Earnings

Qiagen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2024
$483.00M
Adjusted diluted EPS, Q4 FY2024
$0.55
Latest guidance
Issued
Apr 8, 2025 · 2 items

Quarterly results

Revenue and earnings per share from each of Qiagen's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2024ended Dec 31, 2024Apr 9, 2025during market hours$483.00M––$0.55Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Qiagen's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
adjusted operating income marginnon-GAAPFY202530%–NewApr 8, 2025
adjusted diluted EPSnon-GAAPFY2025$2.35–NewApr 8, 2025

Guidance history

Every forecast Qiagen put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Apr 8, 2025adjusted diluted EPSFY2025$2.35New
Apr 8, 2025adjusted operating income marginFY202530%New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Qiagen filed with the SEC as exhibits to Form 8-K or 6-K

  1. 6-K
  2. 6-K
  3. 6-K
  4. 6-K
  5. 6-K
  6. 6-K
  7. 6-K
  8. 6-K
  9. 6-K
  10. 6-K
  11. 6-K
  12. 6-K
  13. 6-K
  14. 6-K
  15. 6-K